Venture-backed, patent protected and award winning med-tech Tournicare successfully raised $2.5m to-date from VC Artesian and other investors
Summary
Tournicare is developing a consumer focused blood pressure (BP) monitor and management system to better serve the ~115 million hypertension sufferers in AU and the US. In the booming tele-monitoring market their solution will provide value for all stakeholders through unique competitive advantages and protected features. Hypertension, or high blood pressure, is the most significant risk factor for the biggest global killer cardiovascular disease (CVD).Tournicare aims to improve all three stages of BP measurement (pre-analytical, analytical and post-analytical).Pre-Analytical & Analytical Benefits result from easy and accurate placement by untrained users of any skill level. This ease of use will increase accuracy and compliance.Post-Analytical Improvements are achieved through personalised BP management including data recording, an interactive app and cloud-based analysis, aiding physicians in efficient and effective hypertension management.Their realistic goal is population-wide lowering of BP to reduce the burden of CVD on our health systems through cost-effective, digitised and personalised healthcare. Tournicare were the winners of the Australian Technology Competition Medtech CategoryTournicare is now raising AU$1.5m via a SAFE with the aim to achieve the following major milestones: